Evidence map›Paper›PMID 41515948›Full record

ArticleInternational journal of molecular sciences2025

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.

Federica Papaccio, Ramona Marrapodi, Laura Eibenschutz, Andrea D'Arino, Silvia Caputo, Alberto Marini, Simona Scano, Arianna Presaghi, Carlo Cota, Elisa Melucci and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Federica PapaccioLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Ramona MarrapodiLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0009-0000-6640-7418
Laura EibenschutzOncologic and Preventative Dermatology, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Andrea D'ArinoOncologic and Preventative Dermatology, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0002-0669-1442
Silvia CaputoLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Alberto MariniLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Simona ScanoLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Arianna PresaghiDepartment of Plastic and Regenerative Surgery, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0009-0007-4108-3104
Carlo CotaGenetic Research, Molecular Biology and Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Elisa MelucciDepartment of Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0003-4908-5271
Stefano ScaleraBiostatistics, Bioinformatics and Clinical Trial Center, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0001-5192-5917
Emilia MiglianoDepartment of Plastic and Regenerative Surgery, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0002-5316-8937
Marcello Maugeri-SaccàBiostatistics, Bioinformatics and Clinical Trial Center, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Pasquale FrascioneOncologic and Preventative Dermatology, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.
Barbara BelleiLaboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0002-3883-5500

Funding

Italian Ministry of Health RC2025
6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer, predominantly affecting sun-exposed areas. It typically grows slowly and rarely metastasizes, though untreated cases can cause significant tissue destruction and morbidity. Its pathogenesis primarily involves dysregulation of the Hedgehog (HH) signaling pathway, mainly through mutations in

Indexed as

Antineoplastic AgentsBasal Cell CarcinomaDrug Resistance, NeoplasmSkin NeoplasmsSmoothened ReceptorBiphenyl CompoundsFemaleHedgehog ProteinsHumansMutationPyridinesSignal TransductionAntineoplastic AgentsBiphenyl CompoundsHedgehog ProteinsPyridinesSmoothened ReceptorSMO protein, humansonidegibbasal cell carcinomadrug resistancehedgehog pathwaytargeted therapies

Identifiers

PMID41515948
PMCPMC12785518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.